SD BioSensor

Historical price data

SD Biosensor is a publicly traded diagnostics powerhouse that leverages its core biosensor and lateral flow assay technologies to develop, manufacture, and commercialize a wide range of diagnostic products. The company achieved significant global scale and recognition through its COVID-19 test kits, supplied worldwide via partnerships with major organizations like Roche and the Bill & Melinda Gates Foundation. Its strategic focus now includes diversifying its infectious disease portfolio, expanding into chronic disease diagnostics, and enhancing its automated diagnostic platforms to drive long-term growth beyond the pandemic.

Core platforms include Lateral Flow Immunoassay (LFIA) for rapid tests, fluorescent/chemiluminescent immunoassay systems for quantitative analysis, and real-time PCR for molecular diagnostics, all supported by large-scale manufacturing.

SD Biosensor competes with global IVD giants like Abbott, Roche, QuidelOrtho, and Siemens Healthineers in rapid and point-of-care testing, and with molecular diagnostics firms like BioMérieux and Cepheid. Its differentiation is built on massive manufacturing scale, cost efficiency, and a broad portfolio spanning simple RDTs to molecular systems.